Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BADBURN)

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT05216133
Status
Enrolling By Invitation

Conditions

  • Airway Disease
  • Barrett Esophagus
  • Gastroesophageal Reflux Disease

Eligibility Criteria

Sex
MALE
Age
37 Years - 90 Years
Healthy Volunteers
Not accepted

Study Details

A majority of Fire Department of New York (FDNY) World Trade Center (WTC) exposed rescue and recovery workers developed gastroesophageal reflux disease (GERD), a risk factor for Barrett's Esophagus (BE) and subsequent esophageal cancer. There is diminished health-related quality of life and productivity associated with aerodigestive diseases such as GERD and BE. This proposal will leverage the longitudinally phenotyped WTC exposed cohort, validate biomarkers of WTC-aerodigestive disease, and develop novel, noninvasive disease phenotyping of premalignant diseases such as BE, and identify potential targeted therapeutics to improve care.

Key Dates

Start date
Mar 22, 2023
Status verified
Apr 2026
Primary completion
Jun 30, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
200 participants (estimated)

Primary Outcome Measure

Levels of salivary pepsin [ Time Frame: up to Day 365 ]

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Clinical & Translational Science Institute Clinical Research Center (CTSI CRC)New YorkNew York10016-

Find similar trials in New York, NY

By research site
NYU Clinical & Translational Science Institute Clinical Research Center (CTSI CRC)· New York, NY

Related Studies